About Us
JYMed Technology Co., Ltd. (hereinafter referred to as “JYMed Peptide“) was founded in 2009, specializing in peptide development and manufacturing. The company has over 600 employees, more than 100 scientists, a 7,000 m² GLP-compliant research laboratory, and an FDA cGMP-compliant API manufacturing site with an annual capacity exceeding 4 tons. As a peptide-only company with over 15 years of experience in peptide development and mass production, JYMed Peptide provides seamless, one-stop services from custom synthesis to commercialization.
Who We Are
Our team of over 600+ professionals, including more than 100 scientists, is led by seasoned experts with 15+ years of experience in the peptide industry. Our core leadership is composed of individuals with deep pharmaceutical backgrounds who guide our strategy, innovation, and operational excellence. We foster a culture of knowledge-sharing and continuous improvement, ensuring we stay at the forefront of peptide science and technology.
JYMed Peptide operates two large-scale production bases and a 7,000-square-meter R&D center equipped with automatic synthesizers, HPLC systems, high-resolution mass spectrometry, and advanced purification platforms. This infrastructure enables us to deliver high-quality peptides at commercial volumes while maintaining rigorous compliance with international standards.
professionals
Scientists
Years of experience
Square-meters R&D Center
Core Values
People First
We place people at the center of everything we do, from our employees and partners to the patients ultimately served by our work. By upholding the highest standards in science, quality, and customer service, we create a culture of trust, respect, and accountability that drives long-term success.
Excellence & Innovation
Our commitment to excellence ensures every project meets the highest regulatory and quality benchmarks. At the same time, we embrace innovation by advancing peptide science through cutting-edge technologies, efficient processes, and continuous improvement. We act with transparency, ethics, and accountability at every stage.
Collaboration & Dedication
We believe strong partnerships are essential to advancing healthcare. By working side by side with our clients, we align with their goals and apply our dedication to deliver reliable, scalable, and sustainable solutions. Our focus is on improving patient outcomes while ensuring secure supply chains and client success worldwide.
What We Do
At JYMed Peptide, we are a biopharmaceutical company with a deep focus on peptide innovation. Since our founding in 2009, we have built state‑of‑the‑art R&D centers and large‑scale manufacturing facilities capable of producing peptides from milligram to metric‑ton scale under strict GMP standards. With a team of seasoned experts and over 20 years of industry experience, we combine scientific excellence, advanced purification technologies, and robust quality systems to deliver reliable, globally compliant solutions. Our infrastructure and capacity enable us to serve partners worldwide, supporting projects from early research through to full commercial supply.
Custom Synthesis
Our custom synthesis services range from milligram-scale research peptides to multi-kilogram and metric-ton GMP production. With strong process control, purification technologies, and advanced analytical capabilities, we meet even the most complex specifications across different applications.
CDMO Services
We offer comprehensive CDMO services tailored to the needs of pharmaceutical companies pursuing both innovative and generic peptide therapeutics. Our contract development and manufacturing capabilities are flexible and scalable, supporting both clinical-phase and commercial programs. With our vertically integrated services, we support clients throughout the full lifecycle of drug development—from discovery and process optimization to commercial manufacturing and global distribution.
Peptide APIs
JYMed Peptide has built a diversified portfolio of over 20 peptide active pharmaceutical ingredients (APIs), including high-demand molecules such as Semaglutide, Tirzepatide, Liraglutide, and Oxytocin. Many of our APIs have Drug Master Files (DMFs) registered with the U.S. FDA, underlining our commitment to global regulatory compliance and product quality.
Cosmetic Peptides
We are a leading supplier of cosmetic peptides, with a strong focus on multifunctional blends for anti-aging, skin repair, and rejuvenation. Our products, such as Copper Peptide and Acetyl Hexapeptide, are used globally by top-tier cosmetic brands for their proven efficacy and safety.
What We Do
At JYMed Peptide, we are a biopharmaceutical company with a deep focus on peptide innovation. Since our founding in 2009, we have built state‑of‑the‑art R&D centers and large‑scale manufacturing facilities capable of producing peptides from milligram to metric‑ton scale under strict GMP standards. With a team of seasoned experts and over 20 years of industry experience, we combine scientific excellence, advanced purification technologies, and robust quality systems to deliver reliable, globally compliant solutions. Our infrastructure and capacity enable us to serve partners worldwide, supporting projects from early research through to full commercial supply.
Custom Synthesis
Our custom synthesis services range from milligram-scale research peptides to multi-kilogram and metric-ton GMP production. With strong process control, purification technologies, and advanced analytical capabilities, we meet even the most complex specifications across different applications.
CDMO Services
We offer comprehensive CDMO services tailored to the needs of pharmaceutical companies pursuing both innovative and generic peptide therapeutics. Our contract development and manufacturing capabilities are flexible and scalable, supporting both clinical-phase and commercial programs. With our vertically integrated services, we support clients throughout the full lifecycle of drug development—from discovery and process optimization to commercial manufacturing and global distribution.
Peptide APIs
JYMed Peptide has built a diversified portfolio of over 20 peptide active pharmaceutical ingredients (APIs), including high-demand molecules such as Semaglutide, Tirzepatide, Liraglutide, and Oxytocin. Many of our APIs have Drug Master Files (DMFs) registered with the U.S. FDA, underlining our commitment to global regulatory compliance and product quality.
Cosmetic Peptides
We are a leading supplier of cosmetic peptides, with a strong focus on multifunctional blends for anti-aging, skin repair, and rejuvenation. Our products, such as Copper Peptide and Acetyl Hexapeptide, are used globally by top-tier cosmetic brands for their proven efficacy and safety.
JYMed Peptide
Over the Years
2024
- Tirzepatide has completed its US-DMF filing.
- Leuprorelin Acetate has passed registration verification.
- The production facilities for Liraglutide, Semaglutide, Tirzepatide, and Oxytocin have obtained WC certification.
- The Hubei JXBio A15 workshop has been completed and is now operational.
2023
The pilot-scale base project jointly submitted by JYMed Peptide and the Pingshan Center was included in the official project funding list.
Semaglutide and Liraglutide were awarded the Guangdong Provincial High-Quality and High-Tech Product Certificate.
Hubei JXBio passed both the Oxytocin registration site inspection and the GMP compliance inspection.
Terlipressin Injection, Carbetocin Injection, and Terlipressin for Injection (single variety) received registration approvals or consistency evaluation/supplementary approvals.
2022
- Multiple APIs and formulations—such as Octreotide Acetate, Desmopressin, Liraglutide, Degarelix Acetate, Bivalirudin, Semaglutide, and others—obtained domestic and international registration approvals or DMF numbers and passed FDA technical reviews or registration inspections.
- Bivalirudin API was approved.
- Terlipressin Injection received a production license.
- Liraglutide and Tirzepatide Injections were approved for clinical use.
2021
- Terlipressin Injection, Carbetocin Injection, and Terlipressin for Injection (single formulation) have received registration approvals or passed consistency evaluations and supplementary approvals.
2020
Terlipressin Injection obtained a production license.
2019
- On May 18, 2019, the first phase of Hubei JXBio Co., Ltd.’s novel peptide APIs industrial park began trial production.
2018
- The first Class I innovative drug, K(D)PT Acetate, received clinical approval.
- The Peptide Products Division once again passed the US FDA on-site audit.
- The “Guangdong Province Synthetic Peptide Innovative Drug Engineering Technology Research Center” was officially approved.
2017
The Peptide Products Division successfully passed its first US FDA on-site quality audit.
2016
- The Peptide Products Division was audited by suppliers from Fresenius Kabi and Pfizer in the United States and was added to their supplier lists.
- On November 27, Hubei JXBio Pharmaceutical Co., Ltd. began construction of the novel peptide APIs industrial park, marking a major milestone in JYMed Peptide’s peptide industrialization.
2015
- Hubei JXBio Pharmaceutical Co., Ltd. was established in Hubei.
- JYMed Peptide officially relocated to the Shenzhen Pingshan Bio-accelerator Industry Park.
- A strategic partnership was established with ROCHEM, enabling JYMed Peptide’s APIs to enter mainstream markets in Europe and America.
2014
- The company established a strategic partnership with ROCHEM, enabling its APIs to enter mainstream markets in Europe and the United States.
2013
- Shenzhen JXBio Pharmaceutical Co., Ltd. was established in Shenzhen.
- The company was certified as a National High-Tech Enterprise.
- The first medicine ANDA application was submitted to the NMPA.
2012
- The company was certified as a High-Tech Enterprise in Shenzhen.
2011
- The company was officially certified as a high‑tech enterprise in Shenzhen.
2010
- The JYMed Peptide Peptide R&D Center was established in the Shenzhen Nanshan High-Tech District Bio-Incubator Base.
2009
- In April 2009, JYMed Technology Co., Ltd. was founded.
